Blue rubber bleb nevus syndrome: an unusual cause of intestinal bleeding in the elderly

Winkler, Jérôme; Bonnet, M; Haffner, Aurélie; Gascou-Tessonnier, Géraldine; Heyries, Laurent; Grandval, Philippe; Mège, Diane

doi:10.1055/a-1381-6267

Cited by 1 publication

(1 citation statement)

References 3 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although aberrant VMs are often congenital and their size and number increase with age, VMs of BRBNS may develop in adult and elderly patients. [6][7][8] Intestinal volvulus, infarction, or intussusception are infrequent complications of GI tract involvement. 9 To date, there is no evidence of a potential malignant evolution of VMs.…”

Section: Introductionmentioning

confidence: 99%

Treatment options for gastrointestinal bleeding blue rubber bleb nevus syndrome: Systematic review

Rimondi

Sorge

Murino

et al. 2023

Digestive Endoscopy

View full text Add to dashboard Cite

ObjectivesBlue rubber bleb nevus syndrome (BRBNS) is a rare challenging cause of gastrointestinal bleeding. We performed a systematic review of case reports and case series on BRBNS to gather information on the treatment options currently available.MethodsAll studies reporting a case of BRBNS in humans were evaluated. Papers were ruled out if CARE criteria and explanations on patient's selection, ascertainment, causality, and reporting were not respected or identified. PROSPERO 2021 CRD 42021286982.ResultsBlue rubber bleb nevus syndrome was treated in 106 cases from 76 reports. 57.5% of the population was under 18 years old, and up to 50% of the cases reported a previous treatment. Clinical success was achieved in 98 patients (92.4%). Three main types of interventions were identified: systemic drug therapy, endoscopy, and surgery. After BRBNS recurrence or previous therapy failure, systemic drug therapy emerged as a preferred second‐line treatment over endoscopy (P = 0.01), but with a higher rate of reported adverse events when compared with surgery and endoscopy (P < 0.001). Endoscopic treatment was associated with a higher number of required sessions to achieve complete eradication when compared with surgery (P < 0.001). No differences between the three main areas were found in the overall follow‐up time (P = 0.19) or in the recurrence rate (P = 0.45).ConclusionEndoscopy, surgery, and systemic drug therapy are feasible treatment options for BRBNS. Systemic drug therapy was the favorite second‐line treatment after endoscopic failure or recurrence of BRBNS, but adverse events were more frequently reported.

show abstract